grants_govHT942526LCRPTRA
Open
DoW Lung Cancer Translational Research Award
- Response deadline
- Sep 2, 2026 Closed
- Date posted
- May 5, 2026
- Source
- Open notice
Description
Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis. Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.
Classifications
- NAICS12.420
Documents (1)
- DownloadHT942526LCRPTRA_GG.pdfapplication/pdf695 KB
Contacts
- help@ebrap.org301-619-1139
Similar contracts
- DoW Breast Cancer, Clinical Research Extension AwardDue Nov 18, 2026
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Due Nov 18, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardDue Nov 4, 2026
- DoW Neurofibromatosis Synergistic Idea AwardDue Sep 22, 2026
- DoW Neurofibromatosis Investigator-Initiated Research AwardDue Sep 22, 2026
- DoW Neurofibromatosis Exploration-Hypothesis Development AwardDue Sep 22, 2026